Osko et al., 2019 - Google Patents
Exploring structural determinants of inhibitor affinity and selectivity in complexes with histone deacetylase 6Osko et al., 2019
View PDF- Document ID
- 8308597908560938534
- Author
- Osko J
- Porter N
- Narayana Reddy P
- Xiao Y
- Rokka J
- Jung M
- Hooker J
- Salvino J
- Christianson D
- Publication year
- Publication venue
- Journal of medicinal chemistry
External Links
Snippet
Inhibition of histone deacetylase 6 (HDAC6) has emerged as a promising therapeutic strategy for the treatment of cancer, chemotherapy-induced peripheral neuropathy, and neurodegenerative disease. The recent X-ray crystal structure determination of HDAC6 …
- 230000002401 inhibitory effect 0 title abstract description 259
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Osko et al. | Exploring structural determinants of inhibitor affinity and selectivity in complexes with histone deacetylase 6 | |
| Ho et al. | Thirty years of HDAC inhibitors: 2020 insight and hindsight | |
| Marek et al. | Characterization of histone deacetylase 8 (HDAC8) selective inhibition reveals specific active site structural and functional determinants | |
| Porter et al. | Entropy as a driver of selectivity for inhibitor binding to histone deacetylase 6 | |
| Osko et al. | Structural basis of catalysis and inhibition of HDAC6 CD1, the enigmatic catalytic domain of histone deacetylase 6 | |
| Porter et al. | Histone deacetylase 6-selective inhibitors and the influence of capping groups on hydroxamate-zinc denticity | |
| Rodrigues et al. | Design, synthesis, and pharmacological evaluation of novel N-acylhydrazone derivatives as potent histone deacetylase 6/8 dual inhibitors | |
| Noonepalle et al. | Rational design of suprastat: a novel selective histone deacetylase 6 inhibitor with the ability to potentiate immunotherapy in melanoma models | |
| Karatas et al. | Discovery of a highly potent, cell-permeable macrocyclic peptidomimetic (MM-589) targeting the WD repeat domain 5 protein (WDR5)–mixed lineage leukemia (MLL) protein–protein interaction | |
| Wang et al. | Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases | |
| Santos-Martins et al. | AutoDock4Zn: an improved AutoDock force field for small-molecule docking to zinc metalloproteins | |
| Pontiki et al. | Histone deacetylase inhibitors (HDACIs). Structure—Activity relationships: History and new QSAR perspectives | |
| Suzuki et al. | Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors | |
| Granchi et al. | Structural optimization of 4-chlorobenzoylpiperidine derivatives for the development of potent, reversible, and selective monoacylglycerol lipase (MAGL) inhibitors | |
| Villadsen et al. | Total synthesis and full histone deacetylase inhibitory profiling of azumamides A–E as well as β2-epi-azumamide E and β3-epi-azumamide E | |
| AU2003274330B2 (en) | Asparaginyl hydroxylases and modulators thereof | |
| Korczynska et al. | Docking and linking of fragments to discover jumonji histone demethylase inhibitors | |
| Giannini et al. | ST7612AA1, a thioacetate-ω (γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors | |
| Decroos et al. | Variable active site loop conformations accommodate the binding of macrocyclic largazole analogues to HDAC8 | |
| Hou et al. | Enhancing the sensitivity of pharmacophore-based virtual screening by incorporating customized ZBG features: a case study using histone deacetylase 8 | |
| Daniel et al. | Dual-mode HDAC prodrug for covalent modification and subsequent inhibitor release | |
| Harding et al. | Small molecule antagonists of the interaction between the histone deacetylase 6 zinc-finger domain and ubiquitin | |
| Salvador et al. | Modulation of activity profiles for largazole-based HDAC inhibitors through alteration of prodrug properties | |
| Fieulaine et al. | A unique peptide deformylase platform to rationally design and challenge novel active compounds | |
| Geurs et al. | The zinc-binding group effect: lessons from non-hydroxamic acid vorinostat analogs |